LUGPA 2025 CME Enduring Program: Operationalizing the Science -Translating New Concepts into Clinical Practice-2025 CME Program Part 1

Video Transcription

Video Summary

The Lugpa CME program, co-chaired by Jason Haffron and Dr. Gordon Brown, focused on the rapid innovation in urology, highlighting new therapies and biomarker-driven trials, especially in bladder cancer. Dr. Piyush Agarwal presented an in-depth overview of nonmuscle-invasive bladder cancer (NMIBC), emphasizing the importance of risk stratification into low, intermediate, and high risk for tailored management. For intermediate-risk NMIBC, treatments include TURBT with perioperative chemotherapy (gemcitabine preferred) and intravesical therapies like BCG or gemcitabine-docetaxel; novel drugs such as UGN-102 (a slow-release chemo gel) and FGFR3-targeted therapies were discussed. High-risk, BCG-naive patients typically require repeat resection and BCG, although shortages have led to alternatives like gemcitabine-docetaxel and new trials combining BCG with immune checkpoint inhibitors (e.g., saselinumab).<br /><br />For BCG-unresponsive disease—traditionally treated with radical cystectomy—new FDA-approved bladder-sparing options include adenoviral gene therapy (nadofaragene), IL-15 fusion proteins with BCG (N803), and intravesical gemcitabine pretzels (TAR-200). Several promising agents and trials are ongoing, expanding treatment choices. However, cystectomy remains the standard of care. The session underscored the evolving bladder cancer landscape, with multiple novel therapies emerging, increasing options for personalized care and improved outcomes.

Keywords

Lugpa CME program

urology innovation

bladder cancer therapies

nonmuscle-invasive bladder cancer

risk stratification NMIBC

BCG-unresponsive bladder cancer treatments

novel bladder cancer therapies